L-asparaginase encapsulated in erythrocytes

Table of contents


On 27 October 2006, orphan designation (EU/3/06/409) was granted by the European Commission to Erytech Pharma S.A., France, for L-asparaginase encapsulated in erythrocytes for the treatment of acute lymphoblastic leukaemia.

Key facts

Active substance
L-asparaginase encapsulated in erythrocytes
Intented use
Treatment of acute lymphoblastic leukaemia
Date of designation
Orphan designation status
EU designation number

Sponsor's contact details

Erytech Pharma S.A.
60, avenue Rockefeller
69008 Lyon
Telephone: +33 4 78 74 44 38
Telefax: +33 4 78 75 56 29

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

Related content

How useful was this page?

Add your rating